BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 29636300)

  • 1. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
    Cremolini C; Loupakis F; Antoniotti C; Lonardi S; Masi G; Salvatore L; Cortesi E; Tomasello G; Spadi R; Zaniboni A; Tonini G; Barone C; Vitello S; Longarini R; Bonetti A; D'Amico M; Di Donato S; Granetto C; Boni L; Falcone A
    Ann Oncol; 2015 Jun; 26(6):1188-1194. PubMed ID: 25712456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
    Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
    Cremolini C; Marmorino F; Loupakis F; Masi G; Antoniotti C; Salvatore L; Schirripa M; Boni L; Zagonel V; Lonardi S; Aprile G; Tamburini E; Ricci V; Ronzoni M; Pietrantonio F; Valsuani C; Tomasello G; Passardi A; Allegrini G; Di Donato S; Santini D; Falcone A;
    BMC Cancer; 2017 Jun; 17(1):408. PubMed ID: 28599628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
    Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
    Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Rossini D; Lonardi S; Antoniotti C; Santini D; Tomasello G; Ermacora P; Germani MM; Bergamo F; Ricci V; Caponnetto S; Moretto R; Zaniboni A; Pietrantonio F; Buonadonna A; Ritorto G; Masi G; Latiano TP; Rapisardi S; Falcone A; Cremolini C
    Br J Cancer; 2021 Jan; 124(1):183-190. PubMed ID: 33024268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
    Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Ning Y; Stintzing S; Heinemann V; Cao S; Zhang W; Yang D; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Tokunaga R; Naseem M; Battaglin F; Cremolini C; Falcone A; Loupakis F; Lenz HJ
    Eur J Cancer; 2020 May; 131():89-97. PubMed ID: 32305727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G).
    Izawa N; Shitara K; Yonesaka K; Yamanaka T; Yoshino T; Sunakawa Y; Masuishi T; Denda T; Yamazaki K; Moriwaki T; Okuda H; Kondoh C; Nishina T; Makiyama A; Baba H; Yamaguchi H; Nakamura M; Hyodo I; Muro K; Nakajima TE
    Target Oncol; 2020 Oct; 15(5):623-633. PubMed ID: 32960408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
    Burge M; Semira C; Lee B; Lee M; Kosmider S; Wong R; Shapiro J; Ma B; Dean AP; Zimet AS; Steel SA; Lok SW; Torres J; Eastgate M; Wong HL; Gibbs P
    Clin Colorectal Cancer; 2018 Sep; 17(3):e593-e599. PubMed ID: 29958812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
    Parikh AR; Lee FC; Yau L; Koh H; Knost J; Mitchell EP; Bosanac I; Choong N; Scappaticci F; Mancao C; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):2988-2995. PubMed ID: 30224341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.